Henlius Delivers On Innovation Agenda In 2021

Revenue At The Chinese Firm Has Increased By 186.3% Year On Year

Henlius has focused its efforts on becoming a fully-fledged biopharmaceutical company during 2021, moving away from its roots as a biosimilar drug company.

Green ascending arrow
Henlius is expanding beyond biosimilars to develop its own innovative biologic products • Source: Alamy

Chinese biopharmaceutical company Shanghai Henlius Biotech increased its revenue 186.3% year-on-year to RMD1.68bn ($264.3m) during 2021 as it sought to evolve “into a more full-fledged biopharma with keener competitiveness.”

During the year, the company progressed 12 clinical projects and received multiple clinical approvals on six candidates and one combination...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Earnings

More from Business